Investor Presentation, page-57

First 57 Last

Share
Profile

Follow
Mattlewy13

1,112 Posts.

427

07/06/20

13:34

Post #: 45085239
Share

Originally posted by milsha77: ↑

hello, agree. I’d not be too concerned about the name- calling it happens a fair bit here, usually means they know you’re right! lot of long term investors I think emotionally connected to the stock and don’t have the tools to counter argue with facts, or very closely connected to company and know they’ve been caught out, so try to undermine the person instead of the argument!

re: your other question about where oncosil got 8.5 months median survival, I believe I know, they’ve used that number a lot in materials I’ve seen as a default control to panco trial and its from the gemcitabine- abraxane arm of MPACT phase 3 trial published few years ago. Big flaw is that was in metastatic pc which as you’ll recognise is completely wrong comparator population. Not valid. They should really be using the phase 2 LAPC trial of gem-abraxane published Jan this year in one of lancet specialty journals (author: Philip, available on line) which is the nearest to a proper control the panco study never had. But When you read the results you’ll realise immediately why the Philip lapc study is never mentioned in company materials and excluded from their meta analysis .....

Expand

Milsha 76 posts on your HotCopper account and every single one down ramping OSL. Not suss in the slightest

OSL Price at posting: 12.5¢ Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

NHF

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Trump is President Again: What Does This Mean for Crypto?

ACW

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial

First 57 Last

Add OSL (ASX) to my watchlist

(20min delay)
Last 0.8¢		Change 0.001(6.67%)		Mkt cap ! $35.79M

Open	High	Low	Value	Volume
0.8¢	0.9¢	0.8¢	$135.0K	16.89M

Buyers (Bids)

No.	Vol.	Price($)
65	28847611	0.7¢

Sellers (Offers)

Price($)	Vol.	No.
0.8¢	500000	1

View Market Depth

No.	Vol.	Price($)
65	28847611	0.007
23	9359399	0.006
18	15830198	0.005
9	9262824	0.004
2	2839966	0.003

Price($)	Vol.	No.
0.008	500000	1
0.009	10737751	12
0.010	13113723	14
0.011	9139301	17
0.012	7560752	5

Last trade - 16.10pm 12/11/2024 (20 minute delay)

OSL (ASX) Chart

Investor Presentation, page-57

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Trump is President Again: What Does This Mean for Crypto?

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Investor Presentation, page-57

Top Stories

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Trump is President Again: What Does This Mean for Crypto?

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News